These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21232563)

  • 1. New protease inhibitors for HCV--help is on the way.
    Fusco DN; Chung RT
    J Hepatol; 2011 Jun; 54(6):1087-9. PubMed ID: 21232563
    [No Abstract]   [Full Text] [Related]  

  • 2. Sofosbuvir/velpatasvir (Epclusa) for hepatitis C.
    Med Lett Drugs Ther; 2016 Aug; 58(1501):107-8. PubMed ID: 27508349
    [No Abstract]   [Full Text] [Related]  

  • 3. A review of HCV protease inhibitors.
    Chen KX; Njoroge FG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
    Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
    Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-free strategies without a nucleoside/nucleotide analogue.
    Welzel TM; Zeuzem S
    Semin Liver Dis; 2014 Feb; 34(1):47-57. PubMed ID: 24782258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
    Kuntzen T; Timm J; Berical A; Lennon N; Berlin AM; Young SK; Lee B; Heckerman D; Carlson J; Reyor LL; Kleyman M; McMahon CM; Birch C; Schulze Zur Wiesch J; Ledlie T; Koehrsen M; Kodira C; Roberts AD; Lauer GM; Rosen HR; Bihl F; Cerny A; Spengler U; Liu Z; Kim AY; Xing Y; Schneidewind A; Madey MA; Fleckenstein JF; Park VM; Galagan JE; Nusbaum C; Walker BD; Lake-Bakaar GV; Daar ES; Jacobson IM; Gomperts ED; Edlin BR; Donfield SM; Chung RT; Talal AH; Marion T; Birren BW; Henn MR; Allen TM
    Hepatology; 2008 Dec; 48(6):1769-78. PubMed ID: 19026009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy.
    Morsica G; Bagaglio S; Uberti-Foppa C; Galli L; Lazzarin A
    J Acquir Immune Defic Syndr; 2009 May; 51(1):106-8. PubMed ID: 19390331
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors.
    Kwong AD; McNair L; Jacobson I; George S
    Curr Opin Pharmacol; 2008 Oct; 8(5):522-31. PubMed ID: 18835365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C: move over interferon.
    Garber K
    Nat Biotechnol; 2011 Nov; 29(11):963-6. PubMed ID: 22068526
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of novel anti-HCV therapies: HCV protease, helicase, and polymerase as therapeutic targets.
    Hong Z; Standring DN; Baroudy B; Lau JY
    Acta Gastroenterol Belg; 2000; 63(2):210-2. PubMed ID: 10925468
    [No Abstract]   [Full Text] [Related]  

  • 11. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
    Pillaiyar T; Namasivayam V; Manickam M
    Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.
    Manns MP; Bourlière M; Benhamou Y; Pol S; Bonacini M; Trepo C; Wright D; Berg T; Calleja JL; White PW; Stern JO; Steinmann G; Yong CL; Kukolj G; Scherer J; Boecher WO
    J Hepatol; 2011 Jun; 54(6):1114-22. PubMed ID: 21145839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic hepatitis C virus infection in the near future.
    Cheinquer H
    Ann Hepatol; 2013; 12(6):854-9. PubMed ID: 24114813
    [No Abstract]   [Full Text] [Related]  

  • 14. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
    Jensen DM; Asselah T; Dieterich D; Foster GR; Sulkowski MS; Zeuzem S; Mantry P; Yoshida EM; Moreno C; Ouzan D; Wright M; Morano LE; Buynak R; Bourlière M; Hassanein T; Nishiguchi S; Kao JH; Omata M; Paik SW; Wong DK; Tam E; Kaita K; Feinman SV; Stern JO; Scherer J; Quinson AM; Voss F; Gallivan JP; Böcher WO; Ferenci P
    Ann Hepatol; 2016; 15(3):333-49. PubMed ID: 27049487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review.
    Wu S; Kanda T; Nakamoto S; Imazeki F; Yokosuka O
    World J Gastroenterol; 2013 Dec; 19(47):8940-8. PubMed ID: 24379619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in São Paulo state.
    Moreira RC; de Torres Santos AP; Lisboa-Neto G; Mendes-Corrêa MCJ; Lemos MF; Malta FM; Santana RAF; Dastoli GTF; de Castro VFD; Pinho JRR
    Arch Virol; 2018 Oct; 163(10):2757-2764. PubMed ID: 29961118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients.
    Nejabat N; Hosseini SY; Sarvari J; Gorzin AA; Fattahi MR; Rasoolian M
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2311-2317. PubMed ID: 31450900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection.
    Tavares RCF; Feldner ACCA; Pinho JRR; Uehara SNO; Emori CT; Carvalho-Filho RJ; Silva ISS; Santana RAF; de Castro VFD; Castoli GTF; Cristovão CU; Ferraz MLCG
    Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):754-758. PubMed ID: 28234637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapeutic strategies in HCV: second-generation protease inhibitors.
    Clark VC; Peter JA; Nelson DR
    Liver Int; 2013 Feb; 33 Suppl 1():80-4. PubMed ID: 23286850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.
    Romano KP; Ali A; Aydin C; Soumana D; Ozen A; Deveau LM; Silver C; Cao H; Newton A; Petropoulos CJ; Huang W; Schiffer CA
    PLoS Pathog; 2012; 8(7):e1002832. PubMed ID: 22910833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.